



## DAFTAR PUSTAKA

- Alemu, A.W., & Sebastián, M.S. 2010. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. *Global Health Action*, 3, 1–10.
- Amuron, B., Levin, J., Birunghi, J., Namara, G., Coutinho, A., Grosskurth, H., & Jaffar, S. 2011. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. *AIDS Res and Ther*, 8(1), 1-8.
- Badie, B.M., Nabaei, G., Rasoolinejad, M., Mirzazadeh, & McFarland, W. 2013. Early loss to follow-up and mortality of HIV-infected patients diagnosed after the era of antiretroviral treatment scale up: a call for re-invigorating the response in Iran. *Int J STD AIDS*, 24(12), 926–930.
- Barry, M., Howe, J.L., Back, D.J., Swart, M., Breckenridge, M., Weller, I.V., Nye, F. 1994. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. *BJCP*, 37(1), 7–12.
- Battegay, M., Nüesch, R., Hirscher, B., & Kaufmann, G.R. 2006. Immunological recovery and antiretroviral therapy in HIV-1 infection. *lancet infection diseases*, 6(2006), 280-287.
- Biadgilign, S., Reda, & Digaffe, T. 2012. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: A retrospective cohort study. *AIDS Research and Therapy*, 9(1), 9-15.
- Boule, A., Schomaker, M., May, M.T., Hogg, R.S., Shepherd, B.E., Monge, S., Garone, D. 2014. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa , Europe , or North America: A Collaborative Analysis of Prospective Studies. *Plos Medicine*, 11(9) 1-14.
- Braitstein, P., Brinkhof, M. W. G., Dabis, F., Schechter, M., Boule, A., Miotti, P., Egger, M. 2006. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet*, 367, 817–824.
- Brinkhof, M.W.G., Rodriguez, P.M., & Egger, M. 2009. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. *PloS One*. 4(6) 1-9.
- Cameron P.U. & Kelly, M. 2009. HIV immunopathology. In *HIV Management in Australasia a guide for clinical care Of Australasian Society for HIV Medicine (ASHM)*: (pp. 19–35).



- Chen, S.C.C., Yu, J.K.-L., Harries, A.D., Bong, C.-N., Kolola-Dzimadzi, R., Tok, T.S., King, C.C., Wang, J.D. (2008). Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. *TM & IH*, 13(4), 513–519.
- Douglas, Pinsky, L., & Harding, P. 2009. HIV AND AIDS. In *The Columbia University Handbook on* (pp. 1–5).
- Gupta, A., Wood, R., Kaplan, R., Bekker, L., & Lawn, S.D. 2013. Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa. *PloS One*, 8(2), 1–8.
- Gutierrez, F., Padilla, S., Masiá, M., Iribarren, J.A., Moreno, S., Viciana, P., Hoyos, P.S. 2006. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. *PloS One*, 1(1), 1-7.
- Hambisa, M.T., Ali, A., & Dessie, Y. 2013. Determinants of Mortality among HIV Positives after Initiating Antiretroviral Therapy in Western Ethiopia: A Hospital-Based Retrospective Cohort Study. *ISRN AIDS*, 1-8.
- Ingle, S.M., May, M.T., Gill, M.J., Mugavero, M.J., Lewden, C., Abgrall, S., Sterne, J.A.C. 2014. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. *Major Article HIV/AIDS*, (59), 1-11.
- Jerene, D., Endale, A., Hailu, Y., & Lindtjørn, B. 2006. Predictors of early death in a cohort of Ethiopian patients treated with HAART. *BMC Inf Dis*, 6, 1-7.
- Johnson, L.F., Mossong, J., Dorrington, R.E., Schomaker, M., Hoffmann, C.J., Keiser, O., Giddy, J. 2013. Life Expectancies of South African Adults Starting Antiretroviral Treatment Collaborative Analysis of Cohort Studies. *PloS Medicine*, 10(4), 1-11.
- Kantipong, P., Murakami, K., Moolphate, S., Aung, M.N., Yamadan N. 2012. Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai , Northern. *HIV/AIDS-Research and Palliative Care*. 2012(4), 159–168.
- Kelly, M. 2009. Natural history of HIV infection. In J. Hoy, S. Lewin, J. J. P. And, & A. Street (Eds.), *HIV Management in Australasia a guide for clinical care Of Australasian Society for HIV Medicine (ASHM); AIDS Medical Unit, Brisbane, QLD* (pp. 37–47).



Kementerian Kesehatan R.I. 2011. Podoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada orang dewasa (pp. 9–49).

Kementerian Kesehatan R.I. 2013. Peraturan Menteri Kesehatan Republik Indonesia tentang penanggulangan HIV dan AIDS Nomor 21 Tahun 2013 (pp. 1–31).

Kementerian Kesehatan R.I. 2014. Laporan Situasi Perkembangan HIV&AIDS Di Indonesia Tahun 2014 (pp. 57–60).

Koh, Y., Haim, H., & Engelman, A. 2011. Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. *Antimicrobial Agents and Chemotherapy*, 55(1), 42–9.

Komati, S., Shaw, P.A., Stubbs, N., Mathibedi, M.J., Malan, L., Sangweni, P., Hassim, S. 2010. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. *AIDS (London, England)*, 24(3), 1849–1855.

Kumar R. 1999. *Research methodology, A step by step guide for beginners*. (pp. 85–87).

Mageda, K., Leyna, G.H., & Mmbaga, E.J. 2012. High Initial HIV / AIDS-Related Mortality and -Its Predictors among Patients on Antiretroviral Therapy in the Kagera Region of Tanzania A Five -Year Retrospective Cohort Study. *AIDS Res and Treat*, 2012, 1-8.

Maggiolo, F., Airoldi, M., Kleinloog, H.D., Callegaro, A., Ravasio, V., Arici, C., Suter, F. 2007. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. *HIV Clinical Trials*, 8(5), 282–292.

Malini B.D., Stephen P.M., Philip, R.F., James, E.R., Christian, O.I., Stephen, S.C. 2010. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. *AIDS Care*. 21(1), 70–77.

Masaisa, F., Gahutu, J.B., Mukibi, J., Delanghe, J., & Philippé, J. 2011. Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. *AJTMH*, 84(3), 456–460.

Mayap, P.V., Yone, P.E.W., Kengne, A. P., & Kuaban, C. 2013. Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde , Cameroon: a retrospective cohort study. *BMJ Open*, 2013(3), 1–7.



Mermin, J., Lule, J., Ekwaru, J. P., Downing, R., Hughes, P., Bunnell, R., Quick, R. 2005. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. *AIDS*, 19(10), 1035–1042.

Michel, L., Giorgi, R., Villes, V., Martin, P.I., Dellamonica, P., Spire, B., Carrieri, M.P. 2009. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART). *Drug and Alcohol Dependence*, 99(1-3), 96–104.

Moore, D.M., Hogg, R.S., Yip, B., Craib, K., Wood, E., & Montaner, J.S.G. 2006. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/mu L. *HIV Medicine*, 7(6), 383–388.

Mulissa, Z., Jerene, D., & Lindtjørn, B. 2010. Patients Present Earlier and Survival Has Improved , but Pre-ART Attrition Is High in a Six-Year HIV Cohort Data from Ethiopia. *PloS One*, 5(10), 1-9.

Ntemgwa, M. L., Toni, T. d'Aquin, Brenner, B. G., Oliveira, M., Asahchop, E. L., Moisi, D., & Wainberg, M.A. 2009. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. *Antimicrobial Agents and Chemotherapy*, 53(2), 708–715.

Obua, C., Kayiwa, J., Waako, P., Tomson, G., Balidawa, H., Chalker, J., Wahlstrom, R. 2014. Improving adherence to antiretroviral treatment in Uganda with a low-resource facility-based intervention. *Global Health Action*, 7(8), 1-9.

Oerlrichs, R. & Xhilaga, M.S. (2009). Basic HIV virology. In *HIV Management in Australasia a guide for clinical care Of Australasian Society for HIV Medicine (ASHM)* (pp. 9–17).

Palombi, L., Marazzi, M.C., Guidotti, G., Germano, P., Buonomo, E., Scarella, P., De Luca, A. 2009. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. *Clinical Infectious Diseases*: An Official Publication of the Infectious Diseases Society of America, 48(1), 115–122.

Plas, H.V.D., Meintjes, G., Schutz, C., Goliath, R., Myer, L., Baatjie, D., Mendelson, M. 2013. Complications of Antiretroviral Therapy Initiation in Hospitalised Patients with HIV-Associated Tuberculosis. *Plos One* 8(2), 6–11.



Pett dan Pierce. 2009. Antiretroviral therapy. In *HIV Management in Australasia a guide for clinical care Of Australasian Society for HIV Medicine (ASHM)* (pp. 59–72).

Ryan, C., Oelrichs, R., & Crowe, S. 2009. Virological diagnostics. In *HIV Management in Australasia a guide for clinical care Of Australasian Society for HIV Medicine (ASHM)* (pp. 49–55).

Salazar L.F., Crosby R.A., dan DiClemente R.J. 2015. Researche methods in health promotion. Second edition. Jossey-Bass. (pp. 98-102)

Saraceni V., Durovni, B., Cavalcante, S.C., Cohn, S., Pacheco, A.G., Lawrence H. Moulton, Chaisson, R.E., & Golub, J.E. 2014. WHO methods and data sources for country-level causes of death 2000-2012. In *Department of Health Statistics and Information Systems WHO, Geneva* (pp. 2–17).

Saraceni V., Durovni, B., Cavalcante, S.C., Cohn, S., Pacheco, A.G., Lawrence H. Moulton, Chaisson, R.E., & Golub, J.E. 2014. Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the TH Rio cohort , Rio de Janeiro , Brazil. *Brazilian JID*, 18(5), 491–495.

Smith, T.K., Twanya, H., Harries, A., Schoutene, E., & Jahn, A. 2010. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. *Malawi Medical Journal: The Journal of Medical Association of Malawi*, 22(2), 49–56.

Tadesse, K., Haile, F., & Hiruy, N. 2014. Predictors of mortality among patients enrolled on antiretroviral therapy in Aksum hospital, Northern Ethiopia: A retrospective cohort study. *PLoS ONE*, 9(1), 1-6.

Takuva, S., Maskew, M., Brennan, A.T., Sanne, I., Macphail, A.P., & Fox, M.P. 2013. Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen. *Journal of Trop Med (Hindawi)*, 2013, 1-6.

Toor, J.S., Singh, S., Sharma, A., & Arora, S.K. 2014. Mycobacterium tuberculosis Modulates the Gene Interactions to Activate the HIV Replication and Faster Disease Progression in a Co-Infected Host. *PloS One*, 9(9), 1–14.

UNAIDS. 2013. Global Report. In *UNAIDS Report on Global AIDS Epidemic 2013* (pp. 4–8).

Villar, S., Sainz, T., Lee, S., Hunt, P.W., Sinclair, E., Shacklett, B.L., Deeks, S.G. 2014. HIV-infected individuals with low CD4/CD8 ratio despite effective



antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. *PLoS Pathogens*, 10(5), 1-15.

WHO. 2007. In HIV/AIDS Programme: Who Case Definitions of HIV For Surveillance And Revised Clinical Staging And Immunological Classification of HIV-Related Disease In Adults And Children (pp. 15–16).

WHO, UNICEF, UNAIDS. 2013. HIV Treatment; GLOBAL UPDATE ON HIV TREATMENT 2013: RESULTS, IMPACT AND OPPORTUNITIES. In *WHO report in partnership with UNICEF and UNAIDS* (pp. 7–8).

Wisaksana, R., Sumantri, R., Indrati, A.R., Zwitser, A., Jusuf, H., Mast, D.Q., van Der Ven, A. 2011. Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. *BMC Infectious Diseases*, 11(1), 1-10.

Wubshet, M., Berhane, Y., Worku, A., Kebede, Y., & Diro, E. (2012). High Loss to Followup and Early Mortality Create Substantial Reduction in Patient Retention at Antiretroviral Treatment Program in North-West Ethiopia, *ISRN AIDS*, 2012, 1-9.

Yuliani F.S. 2014. Faktor-faktor yang berhubungan dengan peningkatan jumlah CD4 > 200 sel/ml pada pasien HIV yang menjalani pengobatan antiretroviral di RSUP Dr. Sardjito, Yogyakarta tahun 2009-2012.